Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.34 -0.07 (-2.90%)
Closing price 03:59 PM Eastern
Extended Trading
$2.34 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.27
$2.37
50-Day Range
$2.06
$2.43
52-Week Range
$1.82
$3.09
Volume
99,244 shs
Average Volume
137,010 shs
Market Capitalization
$95.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 12% of companies evaluated by MarketBeat, and ranked 906th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Oramed Pharmaceuticals.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Oramed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.03% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 4.50%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.03% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 4.50%, indicating that investor sentiment is improving.
  • News Sentiment

    Oramed Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORMP Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
Oramed Pharm Extends Stock Buyback Program
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.42 at the beginning of 2025. Since then, ORMP stock has decreased by 3.3% and is now trading at $2.34.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) issued its quarterly earnings results on Thursday, August, 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01.

Top institutional shareholders of Oramed Pharmaceuticals include BML Capital Management LLC (7.55%), Bank of America Corp DE (0.35%), Peapod Lane Capital LLC (0.21%) and Connor Clark & Lunn Investment Management Ltd. (0.15%). Insiders that own company stock include Michael Rabinowitz and Nadav Kidron.
View institutional ownership trends
.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
8/14/2025
Today
9/15/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
CIK
1176309
Employees
10
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
($0.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.06 million
Net Margins
N/A
Pretax Margin
-1,110.80%
Return on Equity
-19.37%
Return on Assets
-18.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.82
Quick Ratio
26.81

Sales & Book Value

Annual Sales
$1.34 million
Price / Sales
73.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.61 per share
Price / Book
0.67

Miscellaneous

Outstanding Shares
41,000,000
Free Float
33,705,000
Market Cap
$98.81 million
Optionable
Optionable
Beta
1.69

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners